MindWalk Holdings Corp. has entered into a significant multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd to enhance antibody-discovery workflows. This collaboration will leverage MindWalk's AI capabilities, specifically its ReefIQ and LensAI technologies, to support Teva's discovery decisions and accelerate antibody design optimization. The partnership highlights the growing role of artificial intelligence in the pharmaceutical preparations industry.

MindWalk, trading under the ticker HYFT on the Nasdaq, is a Bio-Native AI company focused on integrating AI with biological data to create a connected discovery ecosystem. The company has been collaborating with Teva Australia since 2018, and this new agreement is a continuation of that relationship.

The SEC filing dated November 4, 2026, outlines the terms of this partnership. MindWalk will deploy its ReefIQ technology, which organizes and governs biological context from various data sources, to assist Teva Australia in its antibody-discovery efforts. Jennifer Bath, President and CEO of MindWalk, expressed her enthusiasm for the collaboration, stating, "We are pleased to continue our collaboration with Teva Australia through this defined deployment." She emphasized that the challenge in antibody discovery is not just data generation but effectively connecting and governing that data.

This agreement is expected to provide MindWalk with a recurring revenue stream, a departure from traditional fee-for-service projects that end once deliverables are shipped. Instead, the ReefIQ deployment is designed to support scientists continuously as their programs advance within the agreed scope and under the respective data governance requirements of both companies.

MindWalk's innovative approach to AI in drug discovery aims to help scientists identify the most promising candidates earlier in the process. Anthony Doyle, Vice President of Antibody Discovery at Teva Australia, noted, "The power of AI in drug discovery is not in generating more possibilities; it’s about helping scientists find the ones that matter." This sentiment underscores the strategic importance of MindWalk's technology in enhancing the efficiency of drug discovery.

As part of the agreement, MindWalk will ensure that the deployment adheres to Teva Australia's information security, privacy, and data governance requirements. Financial terms of the deal were not disclosed, but the partnership is expected to strengthen MindWalk's position in the competitive landscape of pharmaceutical preparations.

Looking ahead, MindWalk is reportedly in active discussions with additional life sciences organizations regarding potential ReefIQ deployments. This indicates a growing interest in AI-driven solutions within the pharmaceutical sector, suggesting that MindWalk could expand its influence in the industry.

In summary, this agreement with Teva Australia marks a significant milestone for MindWalk Holdings Corp. as it continues to innovate in the realm of AI and drug discovery. The collaboration not only enhances Teva's capabilities in antibody discovery but also positions MindWalk as a key player in the evolving pharmaceutical preparations landscape.